CollaGenex Pharmaceuticals, Inc. (NASDAQ:CGPI) announced that the U.S. Patent and Trademark Office (USPTO) has published on its website that the Company's patent application No. 10/117,709 will issue on May 1, 2007 as U.S. Patent No. 7,211,267 (the '267 Oracea(R) Patent). This patent covers the use of sub-antimicrobial doses of tetracyclines, including Oracea, for the treatment of acne and acne rosacea. The USPTO published a notice of allowance of the '267 Oracea Patent in November 2006. CollaGenex received FDA approval for Oracea in May 2006 and is currently marketing Oracea to the U.S. dermatology community.
Colin W. Stewart, president and chief executive officer of...
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry